<DOC>
	<DOCNO>NCT00457288</DOCNO>
	<brief_summary>The current study investigate effect TF002 cutaneous mastocytosis cutaneous involvement systemic mastocytosis compare clobetasol proprionate ( positive control ) general skin care product without active ingredient target mastocytosis ( negative control ) base clinical effect Darier´s sign histological evaluation mast cell number skin bioptic material .</brief_summary>
	<brief_title>Efficacy Safety TF002 Cutaneous Mastocytosis</brief_title>
	<detailed_description>This randomise , double-blind , placebo- active-controlled study intra-individual comparison test area . The primary study target evaluate safety efficacy TF002 treatment cutaneous mastocytosis systemic mastocytosis skin involvment . The treatment period 14 day adjust maximum recommended treatment period comparator Dermoxinale® . Since approved therapy indication placebo control design chosen . There report transient treatment effect use high potent steroid like clobetasol mastocytosis . This triggered decision use Dermoxinale® positive control . To validate clinical score use study , surrogate marker describe Darier´s sign ( thermography , volumetric test ) evaluate optionally .</detailed_description>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Cutaneous</mesh_term>
	<mesh_term>Mastocytoma</mesh_term>
	<criteria>Chronic stable symptomatic maculopapulous cutaneous mastocytosis systemic mastocytosis involvement skin positive Darier 's Sign 3 comparable skin lesional area Otherwise healthy accord physical examination Informed consent sign dated Aggressive systemic mastocytosis Other dermatological disease treat skin site Known hypersensitivity study drug component Mental disorder Drug alcohol dependency Any chronic acute illness require systemic treatment might influence outcome study 4 week start treatment study ( investigator 's decision ) . Immunodeficiency include HIV Pregnancy lactation Participation another clinical trial within last 30 day Malignant skin lesion Radiation therapy target area exclude UV therapy longer 4 week start study treatment Dermal comorbidities within target area Any concomitant medication might influence study objective know provoke aggravate mastocytosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Cutaneous Mastocytosis</keyword>
	<keyword>Topical treatment</keyword>
</DOC>